Malignant hemangioendothelioma

H. Ihda, Y. Tokura, M. Fushimi, R. Yokote, H. Hashizume, S. Shirahama, K. Iwatsuki, K. Murakami, M. Takigawa

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background. The administration of interleukin-2 (IL-2) has recently been reported to be favorable for treating malignant hemangioendothelioma (MHE). Methods. Two patients with MHE responded well to intralesional injections of recombinant IL-2 (rIL-2) without major side effects. The purpose of this study was to characterize cells infiltrating the regressing tumor following rIL-2 treatment. Immunohistochemical studies were performed on biopsy specimens taken from rlL-2-injected lesional skin. Results. It was shown that CD8+ lymphocytes and CD56+ natural killer (NK) cells infiltrated at the rIL-2-injection sites, suggesting that these cells contributed to the tumor regression. In addition, MHE cells bore intercellular adhesion molecule-1 (ICAM-1) whose expression was augmented by rIL-2 injections. Conclusions. These findings suggested, that rIL-2 not only induces lymphokine-activated killer (LAK) cells and NK cells, but also facilitates these cytotoxic cells to adhere to MHE cells by enhancing ICAM-1 expression of tumor cells.

Original languageEnglish
Pages (from-to)811-816
Number of pages6
JournalInternational Journal of Dermatology
Volume34
Issue number11
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Hemangioendothelioma
Interleukin-2
Intercellular Adhesion Molecule-1
Natural Killer Cells
Intralesional Injections
Lymphokine-Activated Killer Cells
Neoplasms
Injections
Lymphocytes
Biopsy
Skin

ASJC Scopus subject areas

  • Dermatology

Cite this

Ihda, H., Tokura, Y., Fushimi, M., Yokote, R., Hashizume, H., Shirahama, S., ... Takigawa, M. (1995). Malignant hemangioendothelioma. International Journal of Dermatology, 34(11), 811-816.

Malignant hemangioendothelioma. / Ihda, H.; Tokura, Y.; Fushimi, M.; Yokote, R.; Hashizume, H.; Shirahama, S.; Iwatsuki, K.; Murakami, K.; Takigawa, M.

In: International Journal of Dermatology, Vol. 34, No. 11, 1995, p. 811-816.

Research output: Contribution to journalArticle

Ihda, H, Tokura, Y, Fushimi, M, Yokote, R, Hashizume, H, Shirahama, S, Iwatsuki, K, Murakami, K & Takigawa, M 1995, 'Malignant hemangioendothelioma', International Journal of Dermatology, vol. 34, no. 11, pp. 811-816.
Ihda H, Tokura Y, Fushimi M, Yokote R, Hashizume H, Shirahama S et al. Malignant hemangioendothelioma. International Journal of Dermatology. 1995;34(11):811-816.
Ihda, H. ; Tokura, Y. ; Fushimi, M. ; Yokote, R. ; Hashizume, H. ; Shirahama, S. ; Iwatsuki, K. ; Murakami, K. ; Takigawa, M. / Malignant hemangioendothelioma. In: International Journal of Dermatology. 1995 ; Vol. 34, No. 11. pp. 811-816.
@article{d34f7696e1684af89dd7a460c1f2dcdf,
title = "Malignant hemangioendothelioma",
abstract = "Background. The administration of interleukin-2 (IL-2) has recently been reported to be favorable for treating malignant hemangioendothelioma (MHE). Methods. Two patients with MHE responded well to intralesional injections of recombinant IL-2 (rIL-2) without major side effects. The purpose of this study was to characterize cells infiltrating the regressing tumor following rIL-2 treatment. Immunohistochemical studies were performed on biopsy specimens taken from rlL-2-injected lesional skin. Results. It was shown that CD8+ lymphocytes and CD56+ natural killer (NK) cells infiltrated at the rIL-2-injection sites, suggesting that these cells contributed to the tumor regression. In addition, MHE cells bore intercellular adhesion molecule-1 (ICAM-1) whose expression was augmented by rIL-2 injections. Conclusions. These findings suggested, that rIL-2 not only induces lymphokine-activated killer (LAK) cells and NK cells, but also facilitates these cytotoxic cells to adhere to MHE cells by enhancing ICAM-1 expression of tumor cells.",
author = "H. Ihda and Y. Tokura and M. Fushimi and R. Yokote and H. Hashizume and S. Shirahama and K. Iwatsuki and K. Murakami and M. Takigawa",
year = "1995",
language = "English",
volume = "34",
pages = "811--816",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Malignant hemangioendothelioma

AU - Ihda, H.

AU - Tokura, Y.

AU - Fushimi, M.

AU - Yokote, R.

AU - Hashizume, H.

AU - Shirahama, S.

AU - Iwatsuki, K.

AU - Murakami, K.

AU - Takigawa, M.

PY - 1995

Y1 - 1995

N2 - Background. The administration of interleukin-2 (IL-2) has recently been reported to be favorable for treating malignant hemangioendothelioma (MHE). Methods. Two patients with MHE responded well to intralesional injections of recombinant IL-2 (rIL-2) without major side effects. The purpose of this study was to characterize cells infiltrating the regressing tumor following rIL-2 treatment. Immunohistochemical studies were performed on biopsy specimens taken from rlL-2-injected lesional skin. Results. It was shown that CD8+ lymphocytes and CD56+ natural killer (NK) cells infiltrated at the rIL-2-injection sites, suggesting that these cells contributed to the tumor regression. In addition, MHE cells bore intercellular adhesion molecule-1 (ICAM-1) whose expression was augmented by rIL-2 injections. Conclusions. These findings suggested, that rIL-2 not only induces lymphokine-activated killer (LAK) cells and NK cells, but also facilitates these cytotoxic cells to adhere to MHE cells by enhancing ICAM-1 expression of tumor cells.

AB - Background. The administration of interleukin-2 (IL-2) has recently been reported to be favorable for treating malignant hemangioendothelioma (MHE). Methods. Two patients with MHE responded well to intralesional injections of recombinant IL-2 (rIL-2) without major side effects. The purpose of this study was to characterize cells infiltrating the regressing tumor following rIL-2 treatment. Immunohistochemical studies were performed on biopsy specimens taken from rlL-2-injected lesional skin. Results. It was shown that CD8+ lymphocytes and CD56+ natural killer (NK) cells infiltrated at the rIL-2-injection sites, suggesting that these cells contributed to the tumor regression. In addition, MHE cells bore intercellular adhesion molecule-1 (ICAM-1) whose expression was augmented by rIL-2 injections. Conclusions. These findings suggested, that rIL-2 not only induces lymphokine-activated killer (LAK) cells and NK cells, but also facilitates these cytotoxic cells to adhere to MHE cells by enhancing ICAM-1 expression of tumor cells.

UR - http://www.scopus.com/inward/record.url?scp=0028844072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028844072&partnerID=8YFLogxK

M3 - Article

C2 - 8543420

AN - SCOPUS:0028844072

VL - 34

SP - 811

EP - 816

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 11

ER -